Pink SheetScripMedtech InsightHBW InsightGenerics BulletinIn Vivo

Spotlight

GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines

Business

Deals
Earnings
Manufacturing

Policy & Regulation

Regulatory Landscape
Drug Pricing
IP & Litigation

Tools & Trackers

What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings

Conference Coverage

Partner Insights

Generics Bulletin Perspectives

Exploring market-shifting topics for the off-patent sector.

Generics Bulletin

Medtech Insight

Samsung Bioepis Reveals Ustekinumab Progress

Company Delivers Phase I Data For SB17 Proposed Biosimilar To Stelara

Mar 23 2023

• By David Wallace

Clinical Trial Icon — Samsung Bioepis reports Phase I data for its ustekinumab • Source: Shutterstock

Related Content

Hikma’s US Biosimilars Ambitions Begin With $150m Ustekinumab Deal

Aug 27 2021

Biocon Joins Fray For Denosumab, Ustekinumab Biosimilars

May 06 2022

Alvotech And Teva File US Stelara Rival Ahead Of 2023 Expiry

Jan 06 2023

Rani Therapeutics Gets Ball Rolling On Oral Stelara Biosimilar

Nov 01 2022

Hikma Taps Celltrion Again To Bring In MENA Stelara Biosimilar

Nov 29 2022

Amgen Sued On US Stelara Biosimilar After Providing May 2023 Intent

Dec 01 2022

Fresenius Kabi And Formycon Ally On Stelara Rival

Feb 02 2023

Stada And Alvotech Eye Potential EU Ustekinumab Nod This Year

Feb 09 2023

Related Companies

Samsung Bioepis Co., Ltd.

Additional Topics

Biosimilars Clinical Trials Strategy BioPharmaceutical

More from Biosimilars

More from Products

Twitter feed RSS feed RSS feed

About

About UsOpens in new window
Meet the Team
AdvertiseOpens in new window
Contact Us

Account

My Account
My View
Email Preferences
Start Free TrialOpens in new window

More

Generics Top 50 Ranking
Biosimilars
Generics
Value Added Medicines

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window